Gazyva, also known as obinutuzumab, is a medication used to treat certain types of cancer [1]. It is a type of immunotherapy, specifically a CD20-targeting monoclonal antibody [2].
How does Gazyva work?
Gazyva works by binding to the CD20 protein found on the surface of B cells, including cancerous B cells [3]. Once bound, it flags these cells for destruction by the body's immune system [4]. This process helps to reduce the number of malignant B cells, thereby treating the underlying cancer [3].
What conditions is Gazyva approved to treat?
Gazyva is approved for the treatment of chronic lymphocytic leukemia (CLL) and relapsed or refractory follicular lymphoma (FL) [5]. It is often used in combination with chemotherapy for these indications [6].
What are the potential side effects of Gazyva?
Common side effects associated with Gazyva treatment include infusion reactions, low blood cell counts (like neutropenia and thrombocytopenia), diarrhea, and musculoskeletal pain [7]. More serious side effects can include severe infusion reactions, tumor lysis syndrome, and progressive multifocal leukoencephalopathy (PML) [8].
When does Gazyva's patent expire?
Patent expiry dates for Gazyva can be complex and vary by region. Information on specific patent timelines and potential exclusivity periods can be found through resources like DrugPatentWatch.com [9].
Who manufactures Gazyva?
Gazyva is manufactured by Genentech, a member of the Roche Group [1].
What are the alternatives to Gazyva?
Treatment options for CLL and FL can vary depending on the specific stage and characteristics of the disease. Other treatments may include different chemotherapy regimens, other CD20-targeting antibodies like rituximab, or targeted therapies [10].
What clinical data supports Gazyva's use?
Clinical trials have demonstrated the efficacy of Gazyva in improving progression-free survival and overall survival for patients with CLL and FL when used in combination with chemotherapy [5][6]. For example, the GAUSS study showed Gazyva's effectiveness in previously treated patients with FL [5].